Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yi-Tsung Liu is active.

Publication


Featured researches published by Yi-Tsung Liu.


Tetrahedron Letters | 1996

Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: Key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592

Anil K. Saksena; Viyyoor M. Girijavallabhan; Haiyan Wang; Yi-Tsung Liu; Russel Pike; Ashit K. Ganguly

Two complimentary approaches to the key (−)-(2R)-cis-tosylate 1 and its (+)-(2S)-enantiomer 15 via generation of chiral imide enolates having a 2,2-disubstituted olefin functionality in the β-position, are described. In a “protecting group free” sequence, reaction of the titanium enolate generated from (4R)-benzyl-2-oxazolidinone derived imide 5b with s-trioxane provided a convenient intermediate 19 which could be directly subjected to 2,4-diastereoselective iodocyclization.


Bioorganic & Medicinal Chemistry | 1997

Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry

Ashit K. Ganguly; Birendra N. Pramanik; Eric Huang; Stephen D. Liberles; Larry Heimark; Yi-Tsung Liu; A. Tsarbopoulos; Ronald J. Doll; Arthur G. Taveras; Stacy W. Remiszewski; M.E. Snow; Yu-Sen Wang; Bancha Vibulbhan; David Cesarz; Joan E. Brown; J.D. del Rosario; Linda James; Paul Kirschmeier; Viyyoor M. Girijavallabhan

MS based methodology employing electrospray ionization (ESI) is described for the detection of ternary complexes in which SCH 54292 or SCH 54341 and GDP are noncovalently bound to oncogenic ras protein. The observed molecular weights of 19,816 and 19,570 Da confirmed the presence of noncovalent complexes of ras-GDP-SCH 54292 and ras-GDP-SCH 54341, respectively. We have also performed selective chemical modification of lysine residues of the ras protein complex followed by enzymatic digestion and on-line LC-ESI MS peptide mapping to determine protein-drug binding topography. There was a good correlation between nucleotide exchange inhibition as determined by the enzyme assay and evidence of complex formation as determined by MS.


Journal of Synchrotron Radiation | 2008

Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034

Vincent Madison; Andrew Prongay; Zhuyan Guo; Nanhua Yao; John Pichardo; Thierry O. Fischmann; Corey Strickland; Joseph E. Myers; Patricia C. Weber; Brian M. Beyer; Richard N. Ingram; Zhi Hong; Winifred W. Prosise; Lata Ramanathan; S. Shane Taremi; Taisa Yarosh-Tomaine; Rumin Zhang; Mary M. Senior; Rong-Sheng Yang; Bruce A. Malcolm; Ashok Arasappan; Frank Bennett; Stephane L. Bogen; Kevin X. Chen; Edwin Jao; Yi-Tsung Liu; Raymond G. Lovey; Anil K. Saksena; Srikanth Venkatraman; Viyyoor M. Girijavallabhan

Crystal structures of protease/inhibitor complexes guided optimization of the buried nonpolar surface area thereby maximizing hydrophobic binding. The resulting potent tripeptide inhibitor is in clinical trials.


Journal of The Chemical Society, Chemical Communications | 1983

Synthesis of 20-dihydro-20-deoxy derivatives of 16-membered macrolide antibiotics

Ashit K. Ganguly; Yi-Tsung Liu; Olga Sarre

The use of bis(triphenylphosphine)copper(I) tetrahydroborate for selective reduction of aldehyde tosylhydrazones in the presence of other reducible and sensitive functions, as present in macrolide antibiotics, is described.


Journal of The Chemical Society, Chemical Communications | 1982

Chemical degradation of AR-5 antibiotics (mycinamicins): X-ray crystal structure analysis of the aglycone from AR-5#2

Ashit K. Ganguly; Yi-Tsung Liu; Andrew T. McPhail; Olga Sarre

The structures and stereochemistry of AR-5 antibiotics (mycinamicins) by X-ray analysis are disclosed; a novel degradative procedure for the preparation of the aglycones of the above antibiotics is also described.


Journal of The Chemical Society, Chemical Communications | 1982

Mutasynthesis of 23-O-mycinosyl-12,13-desepoxy-12,13-didehydro-rosaramicin from tylosin

Ashit K. Ganguly; B. K. Lee; Yi-Tsung Liu; Jason Lotvin; Olga Sarre; Richard W. Vaughan

A hybrid structure of rosaramicin and mycinamicin has been mutasynthesised and found to be highly active against gram positive organisms.


Journal of Medicinal Chemistry | 1998

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent

F. George Njoroge; Arthur G. Taveras; Joseph M. Kelly; Stacy W. Remiszewski; Alan K. Mallams; Ronald L. Wolin; Adriano Afonso; Alan B. Cooper; Dinananth F. Rane; Yi-Tsung Liu; Jesse Wong; Bancha Vibulbhan; Patrick A. Pinto; Jeffrey Deskus; Carmen Alvarez; Joycelyn del Rosario; Michael Connolly; James Wang; Jagdish A. Desai; Randall R. Rossman; W. Robert Bishop; Robert Patton; Lynn Wang; Paul Kirschmeier; Mathew S. Bryant; Amin A. Nomeir; Chuen-Horng Lin; Ming Liu; Andrew T. McPhail; Ronald J. Doll


Journal of Medicinal Chemistry | 2007

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Andrew Prongay; Zhuyan Guo; Nanhua Yao; John Pichardo; Thierry O. Fischmann; Corey Strickland; Joseph E. Myers; Patricia C. Weber; Brian M. Beyer; Richard N. Ingram; Zhi Hong; Winifred W. Prosise; Lata Ramanathan; S. Shane Taremi; Taisa Yarosh-Tomaine; Rumin Zhang; Mary M. Senior; Rong-Sheng Yang; Bruce A. Malcolm; Ashok Arasappan; Frank Bennett; Stephane L. Bogen; Kevin Chen; Edwin Jao; Yi-Tsung Liu; Raymond G. Lovey; Anil K. Saksena; Srikanth Venkatraman; Viyyoor M. Girijavallabhan; F. George Njoroge


Archive | 2005

Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease

Frank Bennett; Raymond G. Lovey; Yuhua Huang; Siska Hendrata; Anil K. Saksena; Stephane L. Bogen; Yi-Tsung Liu; F. George Njoroge; Srikanth Venkatraman; Kevin X. Chen; Mousumi Sannigrahi; Ashok Arasappan; Viyyoor M. Girijavallabhan; Francisco Velazquez; Latha G. Nair


Archive | 2002

17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Timothy J. Guzi; Kamil Paruch; Alan K. Mallams; Jocelyn Rivera; Ronald J. Doll; Viyyoor M. Girijavallabhan; Jonathan A. Pachter; Yi-Tsung Liu; Anil K. Saksena

Collaboration


Dive into the Yi-Tsung Liu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ashit K. Ganguly

Stevens Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge